Role of time to progression as a surrogate marker for overall survival in patients with advanced non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Hotta, K.
Kiura, K.
Fujiwara, Y.
Takigawa, N.
Tabata, M.
Ueoka, H.
Tanimoto, M.
机构：
[1] Okayama Univ Hosp, Okayama, Japan
[2] NHO Sanyo Hosp, Ube, Yamaguchi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
    Hotta, Katsuyuki
    Fujiwara, Yoshiro
    Matsuo, Keitaro
    Kiura, Kutsuyuki
    Takigawa, Nagio
    Tabata, Masahira
    Tanimoto, Mitsune
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 311 - 317
  • [2] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Distribution of Immune Markers and Their Association with Overall Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC)
    Kuykendall, Andrew T.
    Khalil, Farah
    Haura, Eric
    Antonia, Scott J.
    Schabath, Matthew
    Gabrilovich, Dmitry
    Creelan, Ben
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S268 - S269
  • [4] Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy.
    Ou, Qiyun
    Yu, Yunfang
    Li, Anlin
    Chen, Yongjian
    Wang, Ying
    Ren, Wei
    Li, Chenchen
    Yao, Herui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Overall survival benefit in advanced non-small-cell lung cancer
    Owen, Olwen Glynn
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 379 - 379
  • [6] Nutritional Risk Status Predicts Overall Survival of Mexican Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Campos-Gomez, S.
    Valdez-Andrade, J. J.
    Esquivel-Gutierrez, J.
    Jaimes Alpizar, E.
    Pacheco-Cuellar, G.
    Campos-Gomez, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S291 - S291
  • [7] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene
    Yoshino, Reiko
    Imai, Hisao
    Mori, Keita
    Takei, Kousuke
    Tomizawa, Mai
    Kaira, Kyoichi
    Yoshii, Akihiro
    Tomizawa, Yoshio
    Saito, Ryusei
    Yamada, Masanobu
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 731 - 736
  • [9] Nondisruptive mutations of TP53 and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Costa, Enric Carcereny
    Bertran-Alamillo, Jordi
    Molina-Vila, Miguel Angel
    Gervais, Radj
    Massuti, Bartomeu
    Bonanno, Laura
    Moran, Teresa
    Majem, Margarita
    Felip, Enriqueta
    Garcia-Campelo, M. Rosario
    Vergnenegre, Alain
    Ramirez, Santiago Viteri
    Gasco, Amaya
    Wannesson, Luciano
    Mayo-de las Casas, Clara
    Pujantell-Pastor, Laia
    Favaretto, Adolfo G.
    Karachaliou, Niki
    Rosell, Rafael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong
    Garcia, Jacob
    Barron, Rich
    Crawford, Jeffrey
    Lymans, Gary
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S891 - S892
12345